Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Recommendation of "Buy" by Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $30.00.

AVTX has been the subject of several analyst reports. Wedbush reissued an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday, March 20th. Jefferies Financial Group initiated coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $23.00 price target for the company. HC Wainwright raised shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price target for the company in a report on Monday, June 2nd. Finally, Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a "buy" rating and a $36.00 target price for the company.

Avalo Therapeutics Stock Performance

NASDAQ AVTX traded up $0.07 during trading hours on Thursday, hitting $5.01. The company had a trading volume of 22,006 shares, compared to its average volume of 64,007. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $16.00. The business has a 50 day moving average of $4.44 and a 200-day moving average of $6.20.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.18). As a group, analysts expect that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds have recently bought and sold shares of the stock. Northern Trust Corp purchased a new position in Avalo Therapeutics during the fourth quarter worth $168,000. Marshall Wace LLP purchased a new stake in Avalo Therapeutics in the 4th quarter worth approximately $114,000. Tower Research Capital LLC TRC grew its stake in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock worth $31,000 after acquiring an additional 3,754 shares during the period. Geode Capital Management LLC grew its stake in Avalo Therapeutics by 937.0% in the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company's stock worth $779,000 after acquiring an additional 94,742 shares during the period. Finally, Affinity Asset Advisors LLC grew its stake in Avalo Therapeutics by 1,123.9% in the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company's stock worth $4,092,000 after acquiring an additional 505,765 shares during the period. Hedge funds and other institutional investors own 87.06% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.